Introducing ZEISS arivis Pro 4.2

Your solution for advanced image analysis and visualization.

When carelessness, forgetfulness and coincidence become the researcher’s best friend

Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advanc...

Improved processes and more

Discover the full potential and benefits.

High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7 combines high speed digitization and outstanding image quality.

The First Multi-Technology System from ZEISS

Microscope and measuring machine in one.

Osäkerhet kring IVF-reform i USA – svenskt bolag backar

Vita huset backar från Donald Trumps vallöfte om att öka tillgången till fertilitetsbehandlingar. Svenskt medicinteknikbolaget faller ytterligare efter beskedet.

New diagnostic test soon ready for the market

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct s...

De får medicinpriset för upptäckt av immuntolerans

Året Nobelpris i fysiologi eller medicin tilldelas Mary Brunkow, Fred Ramsdell och Shimon Sakaguchi.

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Tanklock för dina tankar

I vårt sortiment erbjuder vi ett brett utbud av trycklösa luckor från vår tillverkare Zimmerlin. Luckorna görs i hög kvalité utefter de höga renlighetskrav som ...

Danish obesity success causes recruitment problems in southern Sweden

The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.

Jätteanslag till medicinsk grundforskning – åtta projekt delar på 227 miljoner

Mekanismerna bakom kronisk smärta, en atlas över tarmbarriären och B-cellsminnets outforskade dimensioner är några av de åtta grundforskningsprojekt inom medici...

Danska läkemedelsfonder investerar i talangfabrik

Novo Nordisk Foundation, Lundbeck Foundation och Leo Foundation investerar 123 miljoner danska kronor, motsvarande omkring 188 miljoner svenska kronor, i ett ny...

Krönika: Collaboration across borders

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

One System, Three Contrasting Techniques

ZEISS Axioscan 7 clinical - your digital slide scanner for diagnostics and clinical research.

Björn Arvidsson: ”We need to change perspective”

If you say “life science” to a person on the street and ask them to explain what it is, you will probably get no good answer. The same question to your network ...

Bio Europe intar Stockholm i höst – ”Det svenska ekosystemet tar nu tillfället i akt”

Den internationella life science-konferensen Bio Europe kommer i november för första gången till Sverige. Konferensen, vars program tar inspiration av ABBA-låta...

A new international stem cell research centre has been created in Copenhagen

A new centre for stem cell research opened to the public in January. The Novo Nordisk Foundation backs the initiative with the ambition that the centre will advance new medical technology and ...

Newly discovered gene variant linked to protection against abdominal obesity

American researchers believe they have identified a rare gene mutation that protects against abdominal obesity and metabolic syndrome. The ambition is that the ...

Meet the governmental life science office

More clinical trials, promotion for digitisation and interoperability together with increased use of data generated by both healthcare and individuals. The duti...

He will be the new chair of Medicon Valley Alliance

Niels Abel Bonde is the nomination committee’s proposal and the most likely person to take over as the new chairman of the Swedish-Danish life science cluster o...

Mångmiljardaffär i jakten på nästa blockbuster inom cancer

Bristol Myers Squibb betalar upp till 11,1 miljarder dollar, motsvarande 106 miljarder kronor, för att köpa in sig i en av de hetaste läkemedelskandidaterna inom immunonkologi.